NaiVec Presents Anticancer Drug Platform Achievements at European Cancer Research Society Meeting

[Asia Economy Reporter Hyungsoo Park] Naivec, a peptide fusion bio company, will present research results on its self-developed ‘K-RAS target tumor therapy’ at the invitation of the European Association for Cancer Research (EACR).

Naivec announced on the 26th that it will reveal preclinical research results of the ‘K-RAS mutation target tumor therapy’ applying its own drug delivery platform (NIPEP-TPP) at the European Association for Cancer Research, held for four days from June 20 to 23 (local time) in Seville, Spain.

The K-RAS gene is an oncogene frequently mutated in various cancer types, including lung cancer. Among various K-RAS mutations, the G12C mutation is known to be the most common. The G12C mutation is located deep inside the cell, making it difficult to access.

Recently, Naivec confirmed that its platform can be applied not only to G12C but also to various K-RAS mutations such as G12V and G13D. The company will present research results on this.

Naivec’s drug delivery platform works by binding to biomarkers expressed on the cell surface and then opening the cell membrane with cell-penetrating peptides to deliver the drug. Since NIPEP-TPP possesses precise selective targeting functions and cell and tissue penetration capabilities, it is regarded as a frontrunner in K-RAS anticancer therapy. This is why it was invited to the European Association for Cancer Research.

A Naivec official explained, "In preclinical trials, Naivec’s K-RAS target tumor therapy showed therapeutic effects at lower doses compared to existing drugs," adding, "This means it can overcome side effects caused by high-dose administration."

He continued, "Following the JP Morgan Healthcare Conference, we will present efficacy results in K-RAS models other than lung cancer at this EACR," and "We will also hold meetings with various pharmaceutical companies and biotech firms."

He added, "Until now, most meetings were conducted online," and "Starting this year, along with presenting the research results that had been postponed, we will conduct face-to-face meetings with various company representatives."